Scholarlink

<p>Solid tumors are sustained by profoundly immunosuppressive tumor microenvironments (TMEs) that underlie resistance to immunotherapy. Engineered oncolytic viruses and cytokine-based gene therapies can reprogram the TME, converting ‘cold’ tumors into immune-responsive states and amplifying antitumor immunity. Several agents have achieved regulatory approval, and clinical studies demonstrate that even limited dosing can induce durable changes in immune infiltration and cytokine signaling. Yet consistent and lasting clinical responses remain elusive. Here, we synthesize translational insights from recent trials and highlight emerging strategies to overcome barriers and enhance the therapeutic impact of these TME-modulating biologics.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Oncolytic viruses and cytokine-based gene therapies reprogram the tumor microenvironment

  • 期刊论文

  • 发表日期：

    2026年4月24日

查看全文
  • Joshua D. Bernstock,
  • Lennard Spanehl,
  • E. Antonio Chiocca

摘要

Solid tumors are sustained by profoundly immunosuppressive tumor microenvironments (TMEs) that underlie resistance to immunotherapy. Engineered oncolytic viruses and cytokine-based gene therapies can reprogram the TME, converting ‘cold’ tumors into immune-responsive states and amplifying antitumor immunity. Several agents have achieved regulatory approval, and clinical studies demonstrate that even limited dosing can induce durable changes in immune infiltration and cytokine signaling. Yet consistent and lasting clinical responses remain elusive. Here, we synthesize translational insights from recent trials and highlight emerging strategies to overcome barriers and enhance the therapeutic impact of these TME-modulating biologics.